Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on screen today reasonably aligned with what the business is generating in sales, or has sentiment moved further than the top line can comfortably support? With the stock down 56.4% over the past year, the slide puts fresh focus on whether the present valuation can still be...
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharm
Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of CNY 816.69 million, with a basic loss per share of CNY 2.19. Ascentage Pharma Group International’s recent half year results arrived alongside a sharp move in the stock, with a 1 day share price return of 12.08% and a 7 day share price return of 9.88% at...
Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.
Moby summary of ASCENTAGE PHARMA GROUP INTERNATIONAL's Q2 2026 earnings call
This is the newest page. Registered accounts read further back.